Combination Trastuzumab and Vaccine Therapy to Prevent Disease Recurrence in Locally Advanced HER2+ Breast Cancer

Medicine & Life Sciences

1. Vaccines 100%
2. Trastuzumab 98%
3. Combined Vaccines 98%
4. Active Immunotherapy 94%
5. Breast Neoplasms 63%
6. Recurrence 60%
7. Safety 32%
8. Immunity 27%
9. Hematologic Tests 23%
10. Clinical Trials 21%
11. Neoplasms 17%
12. Vaccination 17%
13. pertuzumab 17%
14. Planets 16%
15. Breast Cancer 3 16%
16. Investigational Drugs 15%
17. Research Personnel 15%
18. Injection Site Reaction 15%
19. Placebos 15%
20. Raloxifene Hydrochloride 15%
21. Immunologic Monitoring 14%
22. Clinical Trials, Phase I 13%
23. Triple Negative Breast Neoplasms 13%
24. Phase III Clinical Trials 13%
25. Organized Financing 13%
26. Preliminary Data 12%
27. Tamoxifen 11%
28. United States Food and Drug Administration 11%
29. Toxicology 10%
30. Communicable Diseases 9%
31. Fatigue 9%
32. Therapeutics 9%
33. Research Design 8%
34. Poisons 8%
35. Animal Models 8%
36. Biomarkers 7%
37. Physicians 7%
38. Neoplasm Metastasis 6%
39. Morbidity 6%
40. Mortality 5%